NEW YORK, Feb. 14 - Fluidigm Corporation will provide microfluidic platform technology, tools, software and customized microfluidic prototype chips for GlaxoSmithKline, the company said.
Terms of the deal call for GSK to use Fluidigm's multi-layer soft lithography technology in pharmaceutical development.
Fluidigm said in a statement on Monday that its platform will allow GSK researchers to redesign chips very quickly-in a matter of weeks, rather than months.
For its part, the pharma giant is working to accelerate drug development by developing microfluidic instruments that are highly automated and can work with small sample volumes.
Financial details of the agreement were not disclosed.
Fluidigm, based in South San Francisco, Calif., develops lab-on-a-chip technology. It has invented a sandwiched rubber chip with built-in microfluidics for applications in mixing and cell sorting and mixing, and intend to adapt the technology for use in protein separation, sample preparation, and single molecule analysis.
The firm signed an agreement with Axon Instruments in July 2001 to develop a cell capture and microfluidics chip for drug discovery.